Multiple sclerosis management during the COVID-19 pandemic
Brandon Moss(Cleveland Clinic), Kathryn C. Fitzgerald(Johns Hopkins University), Daniel Ontaneda(University of British Columbia Hospital), Jaume Sastre‐Garriga(Universitat Autònoma de Barcelona), Marisa McGinley(Cleveland Clinic), Paula Tagliani(Universitat Autònoma de Barcelona), Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya), Le H. Hua(Cleveland Clinic), Kedar Mahajan(Cleveland Clinic), Esther Ogbuokiri(Johns Hopkins University), Mar Tintoré(Vall d'Hebron Hospital Universitari), Pere Carbonell‐Mirabent(MACOM (United States)), Malory Weber(Cleveland Clinic), Jeffrey A. Cohen(Cleveland Clinic), Ana Zabalza(Universitat Autònoma de Barcelona), Kelsey Hellisz(Cleveland Clinic), Marta Rodríguez‐Barranco(Universitat Autònoma de Barcelona), Georgina Arrambide(Universitat Autònoma de Barcelona), Zhini Wang(Cleveland Clinic), Berna Aravidis(Johns Hopkins University), Simón Cárdenas‐Robledo(Universitat Autònoma de Barcelona), Morgan Douglas(Johns Hopkins University), Robert Bermel(Cleveland Clinic), Ellen M. Mowry(Johns Hopkins University), Scott Husak(Cleveland Clinic), Timothy Hudec(Cleveland Clinic)
Cited by 76
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k